title: Treatment strategies in mastocytosis.
abstract: Treatment recommendations for mastocytosis are based mostly on expert opinion rather than evidence obtained from controlled clinical trials. In this article, treatment options for mastocytosis are presented, with a focus on the control of mediator-related symptoms in patients with indolent disease.
authors.affiliation: Department of Dermatology and Allergy, Interdisciplinary Mastocytosis Center Charité, Charité-Universitätsmedizin Berlin, Charitéplatz 1, Berlin 10117, Germany. Electronic address: frank.siebenhaar@charite.de.
authors.forename: Frank
authors.initials: F
authors.lastname: Siebenhaar
authors.affiliation: Division of Rheumatology, Allergy, Immunology, Mastocytosis Center, Harvard Medical School, Brigham and Women's Hospital, 1 Jimmy Fund Way, Room 626B, Boston, MA 02115, USA.
authors.forename: Cem
authors.initials: C
authors.lastname: Akin
authors.affiliation: Department of Dermatology, Allergy Centre, Mastocytosis Centre Odense University Hospital, MastOUH, Odense University Hospital, Sdr. Boulevard 29, Entrance 142, 5000 Odense C, Denmark.
authors.forename: Carsten
authors.initials: C
authors.lastname: Bindslev-Jensen
authors.affiliation: Department of Dermatology and Allergy, Interdisciplinary Mastocytosis Center Charité, Charité-Universitätsmedizin Berlin, Charitéplatz 1, Berlin 10117, Germany.
authors.forename: Marcus
authors.initials: M
authors.lastname: Maurer
authors.affiliation: Department of Dermatology, Allergy Centre, Mastocytosis Centre Odense University Hospital, MastOUH, Odense University Hospital, Sdr. Boulevard 29, Entrance 142, 5000 Odense C, Denmark.
authors.forename: Sigurd
authors.initials: S
authors.lastname: Broesby-Olsen
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000235:genetics / Q000276:immunology; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001842:Bone and Bones / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D002490:Central Nervous System / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D000069439:Dasatinib; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D015870:Gene Expression; D006633:Histamine Antagonists / Q000627:therapeutic use*; D006801:Humans; D008407:Mast Cells / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008415:Mastocytosis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D000069444:Omalizumab; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D011743:Pyrimidines / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D013844:Thiazoles / Q000627:therapeutic use
chemical_list: D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D006633:Histamine Antagonists; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; C026408:anti-IgE antibodies; D000069444:Omalizumab; D019009:Proto-Oncogene Proteins c-kit; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; C526684:PLA2G7 protein, human; C498826:nilotinib; D000069439:Dasatinib
keywords: Anti-IgE; Antihistamine; Antimediator therapy; Mastocytosis; Mediator-related symptoms; Platelet-activating factor